Posts

The First Phase 3 Clinical Trials of "Digital Therapeutics" for Hypertension Begin in Japan

Image
Jichi Medical University and CureApp, Inc.
The First Phase 3 Clinical Trials of "Digital Therapeutics" for Hypertension Begin in Japan
Verifying the standalone therapeutic efficacy of the app in patients untreated with anti hypertensive drugs 
A new treatment for hypertension, the disease with the highest number of patients in Japan, incurring medical costs in the order of $17 billion USD

 CureApp, Inc. (Head Office, Chuo-ku, Tokyo; President and CEO, Kohta Satake, M.D.), developer of software as a medical device “Digital Therapeutics” mobile applications, has launched a Phase 3 multicenter, randomized comparative study (clinical trial) of "Digital Therapeutics“ for hypertension in Japan with various partners including Professor Kazuomi Kario, M.D., Ph.D., the Division of Cardiovascular Medicine, the Department of Medicine, and Jichi Medical University School of Medicine.
 This study will evaluate the efficacy and safety of "Digital Therapeutics" in patients with…

CureApp Announces Results from World’s First Randomized Control Study for Digital Therapeutic Smoking Cessation App

Image
Tokyo, Japan May 30, 2019 – Results from the world’s first randomized control study to examine digital therapeutic smoking cessation programs were presented on May 20th at the American Thoracic Society International Conference. The findings demonstrate that CureApp’s nicotine dependence treatment app resulted in an improvement in continuous abstinence rate (CAR) compared to a control group over multiple time points. Kohta Satake, M.D., M.B.A., M.P.H., Chief Executive Officer of CureApp, Inc. and a respiratory specialized physician says, "Healthcare professionals are challenged to help patients fight against the psychological nicotine addiction alone between clinical visits. CureApp’s digital therapeutics approach is a breakthrough in bridging the gap between clinical visits providing daily support to the patients. We are striving for regulatory and reimbursement approval to deliver the solution as soon as possible.” The CureApp solution delivers information and educational mater…

CureApp Inc., developing “Digital Therapeutics ”, starts joint-development and clinical research of Digital Therapeutics for hypertension with Jichi Medical University.

Image
CureApp Inc. (head office: Chuo-ku, Tokyo, President and CEO: Kota Satake) announced it starts joint-development and clinical research of "Digital Therapeutics" for hypertension with Professor Kazuomi Kario of Cardiovascular Medicine, Jichi Medical University. The clinical research explores the anti-hypertensive effects of the "Digital Therapeutics" and aims to create a novel treatment strategy for hypertension other than medication.

Background

CureApp Inc. aims to create a brand new treatment that is individually optimized (personalized) to achieve a higher therapeutic effect in light of mobile technology evolution. In particular, the scope of treatment encompasses patient awareness, habits and time out in the reach of conventional intervention, such as outside of hospital/clinic, at home, or out of workplace, overarching a wide variety of patients’ life. CureApp acknowledges uniqueness of patient’s individual status and aims to establish a mechanism of’ timely fol…

CureApp and its “Digital Therapeutics”, together with NASH (Non-Alcoholic Steatohepatitis) have launched multi-center clinical trials of their Digital Therapeutics.

Image
CureApp and its “Digital Therapeutics︎︎”, together with NASH (Non-Alcoholic Steatohepatitis)have launched multi-center clinical trials of their Digital Therapeutics. CureApp Co., Ltd (head office: Chuo-ku, Tokyo, President and CEO: Kohta Satake) in collaboration with Koike Kazuhiko and Assistant Professor Masaya Sato from the Department of Gastroenterology and Internal Medicine at the University of Tokyo Hospital, have been carrying out the research and development of “Digital Therapeutics”. We are pleased to inform you that we are starting multiple institutional clinical trials of the (NASH App) Digital Therapeutics, an application dedicated to the treatment of NASH (Non-Alcoholic Steatohepatitis).

This research follows the results of feasibility studies that have been conducted since 2016 at the University of Tokyo Hospital. It is a novel multi institutional clinical research project that has just begun and we aim to continue to obtain evidence to improve our product in a clinical se…

CureApp Satellite Session Present at the 17th World Conference on Tobacco or Health

Image
CureApp Satellite Session Present at the 17th World Conference on Tobacco or Health

CAPE TOWN, South Africa ‒CureApp showcased their breakthrough invention “ Smoking Cessation “ program at the 17th World Conference on Tobacco or Health (WCTOH) in Cape Town, South Africa from March 7-9, 2018.
The WCTOH is the premier international forum on tobacco control that aims to foster regional and international partnerships through exchange and mentorship opportunities. This year, for the first time in its 50-year history, the event was held on the African continent.


The conference brought together 2000 delegates from more than 100 countries, including researchers, academics, non-governmental organizations, civil society, scientists, healthcare professionals and public officials, working on all aspects of tobacco control. As the conference theme “Uniting the World for a Tobacco-Free Generation” suggests, international collaboration is vital for tackling tobacco use, which remains the world’s leadin…

CureApp and HIKARI LAB have began offering the “ascureSPARX Mental Health Program”: A doctor developed application based on cognitive behavior therapy and online counseling.

Image
CureApp and HIKARI LAB have began offering the “ascureSPARX Mental Health Program”: A doctor developed application based on cognitive behavior therapy and online counseling.  



CureApp Co., Ltd. (head office: Chuo-ku, Tokyo, President and CEO: Kouta Satake) which deals with the research and development of “Treatment Applications” as medical devices in treatment programs, together with HIKARI LAB Co., Ltd. (Head office: Chuo-ku, Tokyo, President: Ayako Shimizu) which offers online counselling and smart phone applications for psychological care, have joined together to begin offering the “ascureSPARX Mental Health Program”: A program designed for corporate mental counselling through the combination of specialized applications and online remote guidance.
The “ascureSPARX Mental Health Program” is a psychological care and counseling program that combines a “doctor developed application” and “online counseling”. It provides psychological care based on cognitive behavioral therapy that has bee…

“Cure App Co., Ltd.”which conducts research and development for "Treatment Applications®" issued a third-party allocation of new shares to a total of about 1.5 billion yen

Image
To the press and whom it may concern:
“Cure App Co., Ltd.”which conducts research and development for "Treatment Applications®" issued a third-party allocation of new shares to a total of about 1.5 billion yen

Cure App Co., Ltd. (Head office: Chuo , Tokyo. President and CEO: Kota Satake), which conducts research and development for medical treatment applications for the treatment of disorders, announced today that they are implementing a third-party allocation of new shares of over 1.5 billion yen with newly acquired investors: the ITOCHU Corporation, ITOCHU Technology Ventures, CYBERDYNE Corporation, Dai-ichi Life Insurance Co., Ltd., Mitsubishi UFJ Capital Co., Ltd., Iwashin Business Creation Capital Co., Ltd., Saison Ventures Co., Ltd. (Credit Saison corporate Venture Capital), Chibagin Capital Corporation, Mizuho Capital Corporation in addition to our existing investors, Beyond Next Ventures and Keio Innovation Initiative.
【Background and Purpose · Our Objective】 Cure App is…